TW200501977A - Stabilized composition comprising protein - Google Patents

Stabilized composition comprising protein

Info

Publication number
TW200501977A
TW200501977A TW092126427A TW92126427A TW200501977A TW 200501977 A TW200501977 A TW 200501977A TW 092126427 A TW092126427 A TW 092126427A TW 92126427 A TW92126427 A TW 92126427A TW 200501977 A TW200501977 A TW 200501977A
Authority
TW
Taiwan
Prior art keywords
ifn
agent
level
needed
composition contains
Prior art date
Application number
TW092126427A
Other languages
English (en)
Inventor
Kaori Ikeda
Mariko Tayasu
Yasuhiro Miyako
Hideaki Tai
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of TW200501977A publication Critical patent/TW200501977A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW092126427A 2002-09-26 2003-09-25 Stabilized composition comprising protein TW200501977A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002280157 2002-09-26

Publications (1)

Publication Number Publication Date
TW200501977A true TW200501977A (en) 2005-01-16

Family

ID=32040478

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092126427A TW200501977A (en) 2002-09-26 2003-09-25 Stabilized composition comprising protein

Country Status (4)

Country Link
JP (2) JP5057648B2 (zh)
AU (1) AU2003268664A1 (zh)
TW (1) TW200501977A (zh)
WO (1) WO2004028557A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117948A1 (en) * 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
JP2006137678A (ja) * 2004-11-10 2006-06-01 Shionogi & Co Ltd インターロイキン−２組成物
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
KR100748390B1 (ko) * 2005-11-14 2007-08-10 주식회사 대웅 상피세포성장인자를 포함하는 상처치료용 서방성 필름 제형
JP5137055B2 (ja) * 2006-03-10 2013-02-06 塩野義製薬株式会社 安定化されたインターフェロン−γ組成物
KR100784134B1 (ko) 2006-10-09 2007-12-12 주식회사 대웅 상피세포성장인자를 함유하는 안정한 구내염 치료용 액상조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5834028A (en) * 1993-12-17 1998-11-10 Mochida Pharmaceutical Co., Ltd. Soluble thrombomodulin-containing composition
TW403653B (en) * 1995-12-25 2000-09-01 Otsuka Pharma Co Ltd Dry compositions
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
PT1491208E (pt) * 1999-10-04 2010-05-12 Novartis Vaccines & Diagnostic Composições farmacêuticas contendo polipéptido líquidas estabilizadas
WO2001048117A1 (fr) * 1999-12-24 2001-07-05 Otsuka Pharmaceutical Co., Ltd. Compositions seches contenant un acide amine hydrophobe
PL356641A1 (en) * 1999-12-30 2004-06-28 Chiron Corporation Methods for pulmonary delivery of interleukin-2
CN1147318C (zh) * 2000-01-25 2004-04-28 长春长生基因药业股份有限公司 重组α型干扰素冻干保护剂
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2

Also Published As

Publication number Publication date
JPWO2004028557A1 (ja) 2006-01-19
AU2003268664A1 (en) 2004-04-19
JP2010120966A (ja) 2010-06-03
JP5057648B2 (ja) 2012-10-24
WO2004028557A1 (ja) 2004-04-08

Similar Documents

Publication Publication Date Title
NO20065860L (no) Stabiliserte flytende interferonformuleringer
TW200735897A (en) HFSH aqueous formulation
DK0587858T3 (da) Væksthormonholdig proteinformulering
UA94032C2 (ru) Жидкая стабализированная композиция интерферона без hsa
HUP0303596A2 (hu) Cinkmentes és cinkben szegény, javított stabilitású inzulinkészítmények
WO2003040398A3 (en) Proteins stabilized with polysaccharide gums
IL126463A0 (en) A pharmaceutical formulation containing growth hormone an amino acid and a non-ionic detergent
ATE164760T1 (de) Zubereitung zur kontrollierten freigabe von wirkstoffen für wiederkäuern
DE69715414T2 (de) Stabilisierte pharmazeutische zusammensetzung von bdnf
TW200501977A (en) Stabilized composition comprising protein
DE60200256D1 (de) Fraktion basischer Proteine aus Milch als Wirkstoff zur Reduktion von Bluthochdruck
DE60333868D1 (de) Verwendung von tryptophanreichen peptiden aus molkenproteinhydrolysate zur behandlung von übergewicht und fettleibigkeit
ATE460175T1 (de) Stabile wässrige formulierung von interferon, präparationsmethode und dessen verwendung
DK0759775T3 (da) Flydende IFN-beta-formuleringer
DE602004018496D1 (de) Pharmazeutische zubereitung zur intranasalen applikation von proteinen, enthaltend chitosan oder eines seiner derivate
AR034749A1 (es) Formulaciones de interferon beta humano
WO2004060348A3 (fr) Utilisation ophtalmique et ophtalmologique d’une base nutritive complexe en milieu aqueux
WO2007027092A3 (en) Oral composition for moisturising skin
BR0208554A (pt) Osteoprotegerina no leite
WO2004082707A3 (en) Stabilisation of growth hormones in solution
WO2003102014A3 (en) Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
DE69936190D1 (de) Verwendung von itakonsäure zur regulierung des glykolytischen stoffwechsels
WO2004032863A3 (en) Oral formulations for proteins and polypeptides
DE60200317D1 (de) Formulierung mit gesteuerter Wirkstoffabgabe enthaltend Bupropion-HCI als Wirkstoff
WO2007033020A3 (en) Ophthalmic formulation for treatment of dry eye